These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33520810)

  • 1. Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease.
    Colletta C; Colletta A; Placentino G
    J Diabetes Metab Disord; 2020 Dec; 19(2):883-894. PubMed ID: 33520810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive characterization of graft steatosis after liver transplantation.
    Karlas T; Kollmeier J; Böhm S; Müller J; Kovacs P; Tröltzsch M; Weimann A; Bartels M; Rosendahl J; Mössner J; Berg T; Keim V; Wiegand J
    Scand J Gastroenterol; 2015 Feb; 50(2):224-32. PubMed ID: 25429378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    Liu WY; Zheng KI; Pan XY; Ma HL; Zhu PW; Wu XX; Rios RS; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1057-1064. PubMed ID: 31677195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms.
    Bellan M; Colletta C; Barbaglia MN; Salmi L; Clerici R; Mallela VR; Castello LM; Saglietti G; Carnevale Schianca GP; Minisini R; Pirisi M
    Diabetes Metab J; 2019 Oct; 43(5):700-710. PubMed ID: 31694082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary liver injury and delayed resolution of liver stiffness after alcohol detoxification in heavy drinkers with the
    Rausch V; Peccerella T; Lackner C; Yagmur E; Seitz HK; Longerich T; Mueller S
    World J Hepatol; 2016 Dec; 8(35):1547-1556. PubMed ID: 28050235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
    Wah Kheong C; Nik Mustapha NR; Mahadeva S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [TEN-HOUR INTERMITTENT FASTING PLUS MEDITERRANEAN DIET VERSUS MEDITERRANEAN DIET ALONE FOR TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)].
    Milgrom Y; Massarwa M; Hazou W; Shafrir A; Mishraki E; Sanduka S; Safadi R; Benson A
    Harefuah; 2024 Feb; 163(2):93-96. PubMed ID: 38431857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Synergic Effect of a Nutraceutical Supplementation Associated to a Mediterranean Hypocaloric Diet in a Population of Overweight/Obese Adults with NAFLD.
    Chiurazzi M; Cacciapuoti N; Di Lauro M; Nasti G; Ceparano M; Salomone E; Guida B; Lonardo MS
    Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.
    Lee SS; Byoun YS; Jeong SH; Woo BH; Jang ES; Kim JW; Kim HY
    Dig Dis Sci; 2014 Dec; 59(12):2967-74. PubMed ID: 25069572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease.
    Aller R; Laserna C; Rojo MÁ; Mora N; García Sánchez C; Pina M; Sigüenza R; Durà M; Primo D; Izaola O; de Luis D
    Rev Esp Enferm Dig; 2018 Oct; 110(10):634-640. PubMed ID: 30032630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study.
    Hajiaghamohammadi AA; Ziaee A; Oveisi S; Masroor H
    Hepat Mon; 2012 Aug; 12(8):e6099. PubMed ID: 23087748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
    Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
    Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease.
    Fukui A; Kawabe N; Hashimoto S; Murao M; Nakano T; Shimazaki H; Kan T; Nakaoka K; Ohki M; Takagawa Y; Takamura T; Kamei H; Yoshioka K
    World J Hepatol; 2015 Nov; 7(27):2749-56. PubMed ID: 26644818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease.
    Hotta K; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Chayama K; Nakajima A; Nakao K; Sekine A
    BMC Med Genet; 2010 Dec; 11():172. PubMed ID: 21176169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease.
    Shen J; Wong GL; Chan HL; Chan RS; Chan HY; Chu WC; Cheung BH; Yeung DK; Li LS; Sea MM; Woo J; Wong VW
    J Gastroenterol Hepatol; 2015 Jan; 30(1):139-46. PubMed ID: 25040896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression.
    Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
    Hepatol Res; 2017 Oct; 47(11):1083-1092. PubMed ID: 27862719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.